Treatment as Prevention¨

Gilead reports new data from Discover trial

Gilead Sciences (NASDAQ:GILD) announces findings from the DISCOVER trial evaluating Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets; F/TAF) for HIV pre-exposure prophylaxis (PrEP), showing significant improvements in key measures of bone and renal safety parameters in a subset of study participants who switched from Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate

Gilead reports new data from Discover trial Read More »

The AIDS Pandemic Is Not Over, Says AIDS & LGBT Rights Activist Cleve Jones

In the early ’80s, formerly healthy gay men began developing an unknown disease. Men started dying. What started as a few men, skyrocketed into thousands. Communities in New York, San Francisco, and other U.S. cities were decimated. “We had no effective treatment. We had a government that was not particularly concerned. There was a lot

The AIDS Pandemic Is Not Over, Says AIDS & LGBT Rights Activist Cleve Jones Read More »

Man says his partner never disclosed HIV positive status, which is against the law

AUGUSTA, Ga. (WJBF) – Human immunodeficiency virus ranks high in both Georgia and Richmond County. Many health experts say that’s because people are either not aware of their HIV status or they do not disclose it, which is against the law. One man reached out to NewsChannel 6 and said the lack of disclosure turned

Man says his partner never disclosed HIV positive status, which is against the law Read More »

Why We Still Need a National Gay Men’s HIV/AIDS Awareness Day

Nearly four decades ago, thousands of young healthy gay and bi men suddenly became sick, withered and died. Before doctors and epidemiologists could agree on what the strange illness was, it was called “gay cancer” or Gay Related Immune Deficiency (GRID), later Acquired Immune Deficiency Syndrome (AIDS), and now we know it’s caused by the

Why We Still Need a National Gay Men’s HIV/AIDS Awareness Day Read More »

‘Test and treat’ programmes are failing to reach people at highest risk of HIV transmission

Programmes to scale-up HIV testing and treatment in countries in sub-Saharan Africa may have had less impact on new HIV infections than hoped, partly because they haven’t paid enough attention to groups that contribute disproportionately to HIV acquisition and transmission, experts say. Greater efforts should be made to ensure that ‘universal test and treat’ programmes

‘Test and treat’ programmes are failing to reach people at highest risk of HIV transmission Read More »

Scroll to Top

The British Columbia Centre for Excellence in HIV/AIDS Laboratory has discontinued gp-41 resistance testing as T-20 (enfuvirtide/Fuzeon) is no longer available in Canada as of March 31, 2025